Prometheus Biosciences, Inc.
RXDXNASDAQHealthcare
$199.92
+$0.18(+0.09%)
Market Cap$9.6B
P/E Ratio—
52W High$199.96
52W Low$23.27
Prometheus Biosciences, Inc. (RXDX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RXDX · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2023Report Date: Aug 10, 2023EPS Actual
-$0.86
Est. -$0.91 · +5.5%
Revenue
—
Fiscal Period
Q3 FY2023
FY ends December
Report Date
Aug 10, 2023
After Market Close
▲ Beat EPS🔥 5-Quarter EPS Beat Streak
RXDX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q3 FY2023 | Aug 10, 2023 | -$0.91 | -$0.86 | +5.5% | — | — | — |
| ▲ Q3 FY2023 | Aug 10, 2023 | -$0.91 | -$0.86 | +5.5% | — | — | — |
| ▲ Q2 FY2023 | May 9, 2023 | -$0.92 | -$0.86 | +6.5% | $0.00B | — | — |
| ▲ Q2 FY2023 | May 9, 2023 | -$0.92 | -$0.86 | +6.5% | $0.00B | — | — |
| ▲ Q1 FY2023 | Feb 28, 2023 | -$0.91 | -$0.90 | +1.1% | $0.00B | $0.00B | +25.6% |
| ▼ Q4 FY2022 | Nov 9, 2022 | -$0.89 | -$0.90 | -1.1% | $0.00B | — | — |
| ▲ Q3 FY2022 | Aug 11, 2022 | -$0.92 | -$0.86 | +6.5% | $0.00B | — | — |
| ▼ Q2 FY2022 | May 12, 2022 | -$0.78 | -$0.82 | -5.1% | $0.00B | $0.00B | +4.0% |
Q3 FY2023
Aug 10, 2023Beat
EPS Actual
-$0.86
EPS Est.
-$0.91
EPS Surpr.
+5.5%
Revenue
—
Q3 FY2023
Aug 10, 2023Beat
EPS Actual
-$0.86
EPS Est.
-$0.91
EPS Surpr.
+5.5%
Revenue
—
Q2 FY2023
May 9, 2023Beat
EPS Actual
-$0.86
EPS Est.
-$0.92
EPS Surpr.
+6.5%
Revenue
$0.00B
Q2 FY2023
May 9, 2023Beat
EPS Actual
-$0.86
EPS Est.
-$0.92
EPS Surpr.
+6.5%
Revenue
$0.00B
Q1 FY2023
Feb 28, 2023Beat
EPS Actual
-$0.90
EPS Est.
-$0.91
EPS Surpr.
+1.1%
Revenue
$0.00B
Q4 FY2022
Nov 9, 2022Miss
EPS Actual
-$0.90
EPS Est.
-$0.89
EPS Surpr.
-1.1%
Revenue
$0.00B
Q3 FY2022
Aug 11, 2022Beat
EPS Actual
-$0.86
EPS Est.
-$0.92
EPS Surpr.
+6.5%
Revenue
$0.00B
Q2 FY2022
May 12, 2022Miss
EPS Actual
-$0.82
EPS Est.
-$0.78
EPS Surpr.
-5.1%
Revenue
$0.00B
No analyst estimates available for RXDX.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q3 FY2023 | Aug 10, 2023 | +5.5% | $199.92 | — | — |
| ▲ Q3 FY2023 | Aug 10, 2023 | +5.5% | $199.92 | — | — |
| ▲ Q2 FY2023 | May 9, 2023 | +6.5% | $194.22 | $194.40 | +0.09% |
| ▲ Q2 FY2023 | May 9, 2023 | +6.5% | $194.22 | $194.40 | +0.09% |
| ▲ Q1 FY2023 | Feb 28, 2023 | +1.1% | $118.78 | $122.39 | +3.04% |
| ▼ Q4 FY2022 | Nov 9, 2022 | -1.1% | $47.05 | $49.67 | +5.57% |
| ▲ Q3 FY2022 | Aug 11, 2022 | +6.5% | $49.50 | $47.10 | -4.85% |
| ▼ Q2 FY2022 | May 12, 2022 | -5.1% | $22.39 | $23.57 | +5.27% |
Q3 FY2023—
Report Date
Aug 10, 2023
EPS Beat/Miss
+5.5%
Price Before
$199.92
Price After
—
Q3 FY2023—
Report Date
Aug 10, 2023
EPS Beat/Miss
+5.5%
Price Before
$199.92
Price After
—
Q2 FY2023+0.09%
Report Date
May 9, 2023
EPS Beat/Miss
+6.5%
Price Before
$194.22
Price After
$194.40
Q2 FY2023+0.09%
Report Date
May 9, 2023
EPS Beat/Miss
+6.5%
Price Before
$194.22
Price After
$194.40
Q1 FY2023+3.04%
Report Date
Feb 28, 2023
EPS Beat/Miss
+1.1%
Price Before
$118.78
Price After
$122.39
Q4 FY2022+5.57%
Report Date
Nov 9, 2022
EPS Beat/Miss
-1.1%
Price Before
$47.05
Price After
$49.67
Q3 FY2022-4.85%
Report Date
Aug 11, 2022
EPS Beat/Miss
+6.5%
Price Before
$49.50
Price After
$47.10
Q2 FY2022+5.27%
Report Date
May 12, 2022
EPS Beat/Miss
-5.1%
Price Before
$22.39
Price After
$23.57
Avg Beat Reaction-0.41%
Avg Miss Reaction+5.42%
Beat Rate6 / 8 quarters
Largest Move+5.57% (Q4 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RXDX ends December
Prometheus Biosciences, Inc. (RXDX) most recently reported earnings on August 10, 2023 for Q3 FY2023, posting EPS of $-0.86 — beating the analyst consensus of $-0.91 by +5.5%. RXDX has beaten EPS estimates for 5 consecutive quarters. The next RXDX earnings date is expected around September 1, 2026.
Each quarter, investors track RXDX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RXDX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RXDX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RXDX earnings · 5 questionsPrometheus Biosciences, Inc.'s next earnings report is expected around September 1, 2026. RXDX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RXDX historically reports after market close (AMC).
RXDX earnings datewhen is RXDX earningsRXDX next earnings datewhen does RXDX report earningsRXDX earnings calendar
▸ Source: FMP · Prometheus Biosciences, Inc. SEC filings · US GAAP · Prometheus Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026